R-Biopharm receives approval under CTDA for flu & COVID test

R-Biopharm, a specialist in clinical diagnostics, has announced that the company’s RIDAGENE Flu & SARS-CoV-2 multiplex test (PG6825) has been approved in the UK under the UK Health Security Agency’s Medical Devices CTDA Regulations.

Show CommentsClose Comments

Leave a comment

%d bloggers like this: